This ETF is trying to satisfy appetites for weight loss stocks

Tema ETFs has been capitalizing connected the hazard appetite for value nonaccomplishment stocks.

It is down the GLP-1, Obesity & Cardiometabolic ETF (HRTS), which is up 26% since its inception past November.

The firm's laminitis and CEO Maurits Pot thinks the winning value nonaccomplishment commercialized isn't based connected conscionable hype.

"The companies we way and the companies we put successful are looking not conscionable astatine a value nonaccomplishment approach, but besides different approaches," Pot told CNBC's "ETF Edge" connected Monday. "We could spot a satellite wherever the bulk of the world's colonisation takes a GLP-1, not conscionable for value loss, but for different diseases."

His apical holdings see Mounjaro shaper Eli Lilly and Ozempic and Wegovy shaper Novo Nordisk. Eli Lilly is up 57% truthful acold this year, portion Novo Nordisk is up 38%.

Plus, Pot does not expect the terms tag for GLP-1s to discourage caller patients. He thinks they volition travel down importantly successful the adjacent 2 to 3 years.

"We could spot cause pricing travel down from $12,000 to possibly $6,000 a year, truthful possibly $500 a month," said Pot, who points retired security sum often makes the treatments much affordable to patients.